PMI BioPharma Solutions, formed in January of 2018, has established research and manufacturing operations at multiple sites in Nashville and Celina, TN. A fully qualified staff and lab will offer services from targeted protein research to Phase III clinical trial supplies.
 
PMI BioPharma Solutions began as an internal research, development, and manufacturing site for Berg, LLC, and has since spun off from Berg, LLC and expanded to offer a full range of R&D services associated with drug discovery and development. 
 
PMI Bio’s protein sciences express and purify proteins and develop assays around protein targets using NMR, SPR, crystallography, ITC, (TR)FRET, and DSF.  They provide high throughput library screens and design, develop and test drugs in vitro and in vivo. PMI Bio’s clinical trial production capabilities include bulk liquid manufacturing, aseptic fill and finish and non-aseptic fill and finish for small to medium-scale batches. 
 
“While PMI Bio can offer multiple research and development services for clients, our two distinct areas of expertise are fragment-based drug discovery services and aseptic manufacturing. PMI Bio also has years of expertise in nanosuspensions using microfluidization technologies.  We believe we are well suited to provide competitive, flexible solutions across the drug development space,” said chief executive officer David Sunseri, Ph.D.